The Brazilian Ministry of Health reported 52,160 additional cases and 1,274 more deaths on Tuesday, while a public biomedical center in Sao Paulo state is not ruling out delivering the first doses of a vaccine developed by Chinese pharmaceutical company Sinovac as of January.
This is what the director of the Butantane Institute of Sao Paulo, Dimas Covas, said in an interview for the newspaper ‘Folha de Sao Paulo’ and assured that, despite the fact that “many people say that it is too optimistic for this others could be vaccines, but not for this one, “he said, referring to Sinovac.
Butanam is a public entity dependent on the São Paulo government and dedicated to research in the fields of biology and biomedicine. She has signed an agreement with the Sinovac company to test their potential vaccine on a large scale. So far, trials are being conducted in six states, with up to 9,000 volunteers participating in a dozen research centers.
Covas was very confident with the Chinese company’s development of the vaccine and stated that “it will be the fastest to hit the market”. In turn, he emphasized that in previous studies on 744 people, 90 percent of them had achieved immunity.